Application Detail

Description of Medical Service

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T (CAR-T) cell therapy for treatment of patients with multiple myeloma (MM) who are refractory or have failed more than three lines of prior therapy. The therapy involves taking the patient’s own cells from peripheral blood, enriching them for T-cells (a type of white blood cell that is an essential part of the immune system) and genetically modifying them before infusing them back into the patient to treat the MM.

Description of Medical Condition

Multiple Myeloma (MM) is a cancer affecting a type of white blood cell, known as a plasma cell. Plasma cells are found in the bone marrow and make up a part of the immune system. When cancerous, they accumulate to a point where there is not enough space left for normal, healthy blood cells to be produced. MM can cause bone disease, kidney problems, anaemia, increased risk of infection and blood-clotting.

Reason for Application

Highly Specialised Therapy- National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s

1690

Associated Documentation

PICO Set

PICO Set (PDF 881 KB)
PICO Set (Word 136 KB)

Consultation Survey

Consultation Survey (PDF 658 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Expedited – Bypassing PASC

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 6 October 2023 for it to be considered by MSAC at its November 2023 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Expedited – Bypassing PASC

ESC

5-6 October 2023

MSAC

23-24 November 2023